Application of nanoformulations as a strategy to optimize chemotherapeutic treatment of glioblastoma: a systematic review.

IF 6.4 2区 医学 Q1 ENVIRONMENTAL SCIENCES Journal of Toxicology and Environmental Health-Part B-Critical Reviews Pub Date : 2024-05-18 Epub Date: 2024-03-13 DOI:10.1080/10937404.2024.2326679
Victor Alves de Oliveira, Helber Alves Negreiros, Igor Gabriel Barbosa de Sousa, Layza Karyne Farias Mendes, João Pedro Alves Damaceno Do Lago, Athanara Alves de Sousa, Taline Alves Nobre, Irislene Costa Pereira, Felipe Cavalcanti Carneiro da Silva, Janildo Lopes Magalhães, João Marcelo de Castro E Sousa
{"title":"Application of nanoformulations as a strategy to optimize chemotherapeutic treatment of glioblastoma: a systematic review.","authors":"Victor Alves de Oliveira, Helber Alves Negreiros, Igor Gabriel Barbosa de Sousa, Layza Karyne Farias Mendes, João Pedro Alves Damaceno Do Lago, Athanara Alves de Sousa, Taline Alves Nobre, Irislene Costa Pereira, Felipe Cavalcanti Carneiro da Silva, Janildo Lopes Magalhães, João Marcelo de Castro E Sousa","doi":"10.1080/10937404.2024.2326679","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of this review was to explore the advances of nanoformulations as a strategy to optimize glioblastoma treatment, specifically focusing on targeting and controlling drug delivery systems to the tumor. This review followed the PRISMA recommendations. The studies were selected through a literature search conducted in the electronic databases PubMed Central, Science Direct, Scopus and Web of Science, in April 2023, using the equation descriptors: (nanocapsule OR nanoformulation) AND (glioblastoma). Forty-seven investigations included were published between 2011 and 2023 to assess the application of different nanoformulations to optimize delivery of chemotherapies including temozolomide, carmustine, vincristine or cisplatin previously employed in brain tumor therapy, as well as investigating another 10 drugs. Data demonstrated the possible application of different matrices employed as nanocarriers and utilization of functionalizing agents to improve internalization of chemotherapeutics. Functionalization was developed with the application of peptides, micronutrients/vitamins, antibodies and siRNAs. Finally, this review demonstrated the practical and clinical application of nanocarriers to deliver multiple drugs in glioblastoma models. These nanomodels might ideally be developed using functionalizing ligand agents that preferably act synergistically with the drug these agents carry. The findings showed promising results, making nanoformulations one of the best prospects for innovation and improvement of glioblastoma treatment.</p>","PeriodicalId":49971,"journal":{"name":"Journal of Toxicology and Environmental Health-Part B-Critical Reviews","volume":" ","pages":"131-152"},"PeriodicalIF":6.4000,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Toxicology and Environmental Health-Part B-Critical Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10937404.2024.2326679","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENVIRONMENTAL SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

The aim of this review was to explore the advances of nanoformulations as a strategy to optimize glioblastoma treatment, specifically focusing on targeting and controlling drug delivery systems to the tumor. This review followed the PRISMA recommendations. The studies were selected through a literature search conducted in the electronic databases PubMed Central, Science Direct, Scopus and Web of Science, in April 2023, using the equation descriptors: (nanocapsule OR nanoformulation) AND (glioblastoma). Forty-seven investigations included were published between 2011 and 2023 to assess the application of different nanoformulations to optimize delivery of chemotherapies including temozolomide, carmustine, vincristine or cisplatin previously employed in brain tumor therapy, as well as investigating another 10 drugs. Data demonstrated the possible application of different matrices employed as nanocarriers and utilization of functionalizing agents to improve internalization of chemotherapeutics. Functionalization was developed with the application of peptides, micronutrients/vitamins, antibodies and siRNAs. Finally, this review demonstrated the practical and clinical application of nanocarriers to deliver multiple drugs in glioblastoma models. These nanomodels might ideally be developed using functionalizing ligand agents that preferably act synergistically with the drug these agents carry. The findings showed promising results, making nanoformulations one of the best prospects for innovation and improvement of glioblastoma treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
应用纳米制剂作为优化胶质母细胞瘤化疗的策略:系统综述。
本综述旨在探讨纳米制剂作为优化胶质母细胞瘤治疗策略的进展,尤其侧重于靶向和控制肿瘤给药系统。本综述遵循 PRISMA 建议。这些研究是通过 2023 年 4 月在电子数据库 PubMed Central、Science Direct、Scopus 和 Web of Science 中使用等式描述符进行文献检索筛选出来的:(纳米胶囊或纳米制剂)和(胶质母细胞瘤)。收录的 47 项研究发表于 2011 年至 2023 年期间,目的是评估不同纳米制剂的应用情况,以优化化疗药物的给药,包括以前用于脑肿瘤治疗的替莫唑胺、卡莫司汀、长春新碱或顺铂,以及对另外 10 种药物的研究。数据显示,不同的基质可用作纳米载体,并利用功能化制剂改善化疗药物的内化。功能化是通过应用肽、微量营养素/维生素、抗体和 siRNAs 发展起来的。最后,本综述展示了纳米载体在胶质母细胞瘤模型中递送多种药物的实际和临床应用。开发这些纳米模型时,最好使用功能化配体制剂,这些制剂最好能与所携带的药物发挥协同作用。研究结果表明,纳米制剂前景广阔,是胶质母细胞瘤治疗创新和改进的最佳选择之一。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
13.80
自引率
6.90%
发文量
13
审稿时长
>24 weeks
期刊介绍: "Journal of Toxicology and Environmental Health: Part B - Critical Reviews" is an academic journal published by Taylor & Francis, focusing on the critical examination of research in the areas of environmental exposure and population health. With an ISSN identifier of 1093-7404, this journal has established itself as a significant source of scholarly content in the field of toxicology and environmental health. Since its inception, the journal has published over 424 articles that have garnered 35,097 citations, reflecting its impact and relevance in the scientific community. Known for its comprehensive reviews, the journal also goes by the names "Critical Reviews" and "Journal of Toxicology & Environmental Health, Part B, Critical Reviews." The journal's mission is to provide a platform for in-depth analysis and critical discussion of the latest findings in toxicology, environmental health, and related disciplines. By doing so, it contributes to the advancement of knowledge and understanding of the complex interactions between environmental factors and human health, aiding in the development of strategies to protect and improve public health.
期刊最新文献
Neutrophils in toxicology: a forgotten field. Neuroendocrine contribution to sex-related variations in adverse air pollution health effects. Local and systemic effects of microplastic particles through cell damage, release of chemicals and drugs, dysbiosis, and interference with the absorption of nutrients. Incorporating new approach methods (NAMs) data in dose-response assessments: The future is now! In vitro models to evaluate multidrug resistance in cancer cells: Biochemical and morphological techniques and pharmacological strategies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1